In non-small cell lung cancer (NSCLC), KRAS is mutated in around one third of patients, much more frequently than other oncogenic drivers e.g. EGFR (~15%), ALK rearrangements (~5%), MET mutations (~3%), for which targeted therapies are available [7]. This evidence concerns the gene ALK and non-small cell lung carcinoma.